1 September 2021 in Current Protein & Peptide Science
: The approval of istradefylline, an adenosine 2A receptor (A2AR) antagonist, as an addon treatment in adult patients with Parkinson’s disease by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), is the latest proof of the importance of the adenosinergic system in the nervous system. Adenosine is an endogenous purine nucleoside with a role as a modulator of both neurotransmission and the inflammatory response. As such, the expression pattern of the 4 adenosine receptors (A1R, A2AR, A2BR and A3R) and the extracellular adenosine levels have attracted great interest in the pathogenesis and possible treatment of rare neurodegenerative diseases with motor symptoms. These include Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Restless Legs Syndrome (RLS) and Machado-Joseph Disease (MJD, also known as spinocerebellar ataxia type 3, SCA3). In this review, we shall focus on the role of the different adenosine receptor subtypes in the development and possible treatment of the aforementioned rare neurodegenerative diseases with motor symptoms using the currently available data. The last section discusses the possibility of a role for the adenosine receptors in the treatment of other rare diseases based on the available molecular pathology knowledge.
10 April 2025 in American Journal of Sports Science
AHAlejandra Hernandez-Bueno
Alejandra Hernandez-Bueno
+1
Background: Creatine is one of the most widespread dietary supplements among athletes and weightlifters. It is most commonly administered as creatine monohydrate, which transforms into phosphocreatine once within the muscle, which leads to the production of adenosine triphosphate (ATP). Clonapure® is a functional ingredient which consists of a combination of creatine monohydrate, phosphate salt and phosphocreatine. It is believed that Clonapure® has an impact on muscular ATP synthesis due to its phosphocreatine content. A comparative in vitro study was carried to evaluate the potential effect of Clonapure® on ATP synthesis versus creatine monohydrate. Methods: A C2C12 myoblast cell line finally differentiated into myotubes was used. Bioaviability of samples was measured at 24h through biocompatibility studies. Myotubes were also exposed to samples at different concentrations for 2h and intracellular ATP levels were evaluated througha ergular validated luminescence methos. Glucose was used as positive control. Results: The increase in intracellular ATP levels induced by Clonapure® was 10% higher than the caused by creatine monohydrate and glucose, which both showed similar effects in ATP synthesis. The combination of creatine-phosphate phosphate and creatine monohydrate contained in Clonapure® triggers the intracellular ATP production cascade more efficiently in muscle cells. Dose response analysis revealed that Clonapure® supplementation could boost conveniently physical activities related to endurance and performance.